AAAAAA

   
Results: 1-20 |
Results: 20
Oxo-piperazine derivatives of N-arylpiperazinones as inhibitors of farnesyltransferase
Authors: Dinsmore, CJ Bergman, JM Wei, DD Zartman, CB Davide, JP Greenberg, IB Liu, DM O'Neill, TJ Gibbs, JB Koblan, KS Kohl, NE Lobell, RB Chen, IW McLoughlin, DA Olah, TV Graham, SL Hartman, GD Williams, TM
Citation: Cj. Dinsmore et al., Oxo-piperazine derivatives of N-arylpiperazinones as inhibitors of farnesyltransferase, BIOORG MED, 11(4), 2001, pp. 537-540
Evaluation of amino acid-based linkers in potent macrocyclic inhibitors offarnesyl-protein transferase
Authors: Beshore, DC Bell, IM Dinsmore, CJ Homnick, CF Culberson, JC Robinson, RG Fernandes, C Walsh, ES Abrams, MT Bhimnathwala, HG Davide, JP Ellis-Hutchings, MS Huber, HA Koblan, KS Buser, CA Kohl, NE Lobell, RB Chen, IW McLoughlin, DA Olah, TV Graham, SL Hartman, GD Williams, TM
Citation: Dc. Beshore et al., Evaluation of amino acid-based linkers in potent macrocyclic inhibitors offarnesyl-protein transferase, BIOORG MED, 11(14), 2001, pp. 1817-1821
Aryloxy substituted N-arylpiperazinones as dual inhibitors of farnesyltransferase and geranylgeranyltransferase-I
Authors: Bergman, JM Abrams, MT Davide, JP Greenberg, IB Robinson, RG Buser, CA Huber, HE Koblan, KS Kohl, NE Lobell, RB Graham, SL Hartman, GD Williams, TM Dinsmore, CJ
Citation: Jm. Bergman et al., Aryloxy substituted N-arylpiperazinones as dual inhibitors of farnesyltransferase and geranylgeranyltransferase-I, BIOORG MED, 11(11), 2001, pp. 1411-1415
Design and biological activity of (S)-4-(5-{[1-(3-chlorobenzyl)-2-oxopyrrolidin-3-ylamino]methyl}imidazol-1-ylmethyl)benzonitrile, a 3-aminopyrrolidinone farnesyltransferase inhibitor with excellent cell potency
Authors: Bell, IM Gallicchio, SN Abrams, M Beshore, DC Buser, CA Culberson, JC Davide, J Ellis-Hutchings, M Fernandes, C Gibbs, JB Graham, SL Hartman, GD Heimbrook, DC Homnick, CF Huff, JR Kassahun, K Koblan, KS Kohl, NE Lobell, RB Lynch, JJ Miller, PA Omer, CA Rodrigues, AD Walsh, ES Williams, TM
Citation: Im. Bell et al., Design and biological activity of (S)-4-(5-{[1-(3-chlorobenzyl)-2-oxopyrrolidin-3-ylamino]methyl}imidazol-1-ylmethyl)benzonitrile, a 3-aminopyrrolidinone farnesyltransferase inhibitor with excellent cell potency, J MED CHEM, 44(18), 2001, pp. 2933-2949
Anions modulate the potency of geranylgeranyl-protein transferase I inhibitors
Authors: Huber, HE Robinson, RG Watkins, A Nahas, DD Abrams, MT Buser, CA Lobell, RB Patrick, D Anthony, NJ Dinsmore, CJ Graham, SL Hartman, GD Lumma, WC Williams, TM Heimbrook, DC
Citation: He. Huber et al., Anions modulate the potency of geranylgeranyl-protein transferase I inhibitors, J BIOL CHEM, 276(27), 2001, pp. 24457-24465
Conformational restriction of flexible ligands guided by the transferred NOE experiment: Potent macrocyclic inhibitors of farnesyltransferase
Authors: Dinsmore, CJ Bogusky, MJ Culberson, JC Bergman, JM Homnick, CF Zartman, CB Mosser, SD Schaber, MD Robinson, RG Koblan, KS Huber, HE Graham, SL Hartman, GD Huff, JR Williams, TM
Citation: Cj. Dinsmore et al., Conformational restriction of flexible ligands guided by the transferred NOE experiment: Potent macrocyclic inhibitors of farnesyltransferase, J AM CHEM S, 123(9), 2001, pp. 2107-2108
Antitumor efficacy of a farnesyltransferase inhibitor in transgenic mice
Authors: Gibbs, JB Graham, SL Hartman, GD Koblan, KS Kohl, NE Omer, C Pellicier, A Windle, J Oliff, A
Citation: Jb. Gibbs et al., Antitumor efficacy of a farnesyltransferase inhibitor in transgenic mice, CANC DRUG, 8, 2001, pp. 65-70
alpha(v)beta(3) integrin antagonists as inhibitors of bone resorption
Authors: Hartman, GD Duggan, ME
Citation: Gd. Hartman et Me. Duggan, alpha(v)beta(3) integrin antagonists as inhibitors of bone resorption, EXPERT OP I, 9(6), 2000, pp. 1281-1291
Nonpeptide GPIIB/IIIA receptor antagonists. Part 21: C-6 flexibility and amide bond orientation are important factors in determining the affinity of compounds for activated or resting platelet receptors
Authors: Egbertson, MS Bednar, B Askew, BC Bednar, RA Brashear, K Breslin, MJ Duggan, ME Fisher, TE Halczenko, W Hutchinson, JH Ihle, N Prugh, JD Wai, JS Gould, RJ Hartman, GD
Citation: Ms. Egbertson et al., Nonpeptide GPIIB/IIIA receptor antagonists. Part 21: C-6 flexibility and amide bond orientation are important factors in determining the affinity of compounds for activated or resting platelet receptors, BIOORG MED, 10(17), 2000, pp. 1943-1948
Nonpeptide alpha(v)beta(3) antagonists. 1. Transformation of a potent, integrin-selective alpha(IIb)beta(3) antagonist into a potent alpha(v)beta(3) antagonist
Authors: Duggan, ME Duong, LT Fisher, JE Hamill, TG Hoffman, WF Huff, JR Ihle, NC Leu, CT Nagy, RM Perkins, JJ Rodan, SB Wesolowski, G Whitman, DB Zartman, AE Rodan, GA Hartman, GD
Citation: Me. Duggan et al., Nonpeptide alpha(v)beta(3) antagonists. 1. Transformation of a potent, integrin-selective alpha(IIb)beta(3) antagonist into a potent alpha(v)beta(3) antagonist, J MED CHEM, 43(20), 2000, pp. 3736-3745
Diet of the mole scalopus aquaticus from the Coastal Plain region of SouthCarolina
Authors: Hartman, GD Whitaker, JO Munsee, JR
Citation: Gd. Hartman et al., Diet of the mole scalopus aquaticus from the Coastal Plain region of SouthCarolina, AM MIDL NAT, 144(2), 2000, pp. 342-351
Nonpeptide glycoprotein IIB/IIIA inhibitors. 19. A new design paradigm employing linearly minimized, centrally constrained, exosite inhibitors.
Authors: Hartman, GD Duggan, ME Hoffman, WF Meissner, RJ Perkins, JJ Zartman, AE Naylor-Olsen, AM Cook, JJ Glass, JD Lynch, RJ Zhang, GX Gould, RJ
Citation: Gd. Hartman et al., Nonpeptide glycoprotein IIB/IIIA inhibitors. 19. A new design paradigm employing linearly minimized, centrally constrained, exosite inhibitors., BIOORG MED, 9(6), 1999, pp. 863-868
Imidazole-containing diarylether and diarylsulfone inhibitors of farnesyl-protein transferase
Authors: Dinsmore, CJ Williams, TM O'Neill, TJ Liu, DM Rands, E Culberson, JC Lobell, RB Koblan, KS Kohl, NE Gibbs, JB Oliff, AI Graham, SL Hartman, GD
Citation: Cj. Dinsmore et al., Imidazole-containing diarylether and diarylsulfone inhibitors of farnesyl-protein transferase, BIOORG MED, 9(23), 1999, pp. 3301-3306
Non-thiol 3-aminomethylbenzamide inhibitors of farnesyl-protein transferase
Authors: Ciccarone, TM MacTough, SC Williams, TM Dinsmore, CJ O'Neill, TJ Shah, D Culberson, JC Koblan, KS Kohl, NE Gibbs, JB Oliff, AI Graham, SL Hartman, GD
Citation: Tm. Ciccarone et al., Non-thiol 3-aminomethylbenzamide inhibitors of farnesyl-protein transferase, BIOORG MED, 9(14), 1999, pp. 1991-1996
Non-peptide fibrinogen receptor antagonists. 4(1). The synthesis of [H-3]L-756,568.
Authors: Hamill, TG Hutchinson, JH Brashear, KM Hartman, GD
Citation: Tg. Hamill et al., Non-peptide fibrinogen receptor antagonists. 4(1). The synthesis of [H-3]L-756,568., J LABEL C R, 42(6), 1999, pp. 605-609
N-arylpiperazinone inhibitors of farnesyltransferase: Discovery and biological activity
Authors: Williams, TM Bergman, JM Brashear, K Breslin, MJ Dinsmore, CJ Hutchinson, JH MacTough, SC Stump, CA Wei, DD Zartman, CB Bogusky, MJ Culberson, JC Buser-Doepner, C Davide, J Greenberg, IB Hamilton, KA Koblan, KS Kohl, NE Liu, DM Lobell, RB Mosser, SD O'Neill, TJ Rands, E Schaber, MD Wilson, F Senderak, E Motzel, SL Gibbs, JB Graham, SL Heimbrook, DC Hartman, GD Oliff, AI Huff, JR
Citation: Tm. Williams et al., N-arylpiperazinone inhibitors of farnesyltransferase: Discovery and biological activity, J MED CHEM, 42(19), 1999, pp. 3779-3784
Non-peptide GPIIb/IIIa inhibitors. 20. Centrally constrained thienothiophene alpha-sulfonamides are potent, long acting in vivo inhibitors of platelet aggregation. (vol 42, pg 2409, 1999)
Authors: Egbertson, MS Cook, JJ Bednar, B Prugh, JD Bednar, RA Gaul, SL Gould, RJ Hartman, GD Homnick, CF Holahan, MA Libby, LA Lynch, JJ Lynch, RJ Sitko, GR Stranieri, MT Vasallo, LM
Citation: Ms. Egbertson et al., Non-peptide GPIIb/IIIa inhibitors. 20. Centrally constrained thienothiophene alpha-sulfonamides are potent, long acting in vivo inhibitors of platelet aggregation. (vol 42, pg 2409, 1999), J MED CHEM, 42(19), 1999, pp. 4014-4014
Design and in vivo analysis of potent non-thiol inhibitors of farnesyl protein transferase
Authors: Anthony, NJ Gomez, RP Schaber, MD Mosser, SD Hamilton, KA O'Neil, TJ Koblan, KS Graham, SL Hartman, GD Shah, D Rands, E Kohl, NE Gibbs, JB Oliff, AI
Citation: Nj. Anthony et al., Design and in vivo analysis of potent non-thiol inhibitors of farnesyl protein transferase, J MED CHEM, 42(17), 1999, pp. 3356-3368
Non-peptide GPIIb IIIa inhibitors. 20. Centrally constrained thienothiophene alpha-sulfonamides are potent, long acting in vivo inhibitors of platelet aggregation
Authors: Egbertson, MS Cook, JJ Bednar, B Prugh, JD Bednar, RA Gaul, SL Gould, RJ Hartman, GD Homnick, CF Holahan, MA Libby, LA Lynch, JJ Lynch, RJ Sitko, GR Stranieri, MT Vassallo, LM
Citation: Ms. Egbertson et al., Non-peptide GPIIb IIIa inhibitors. 20. Centrally constrained thienothiophene alpha-sulfonamides are potent, long acting in vivo inhibitors of platelet aggregation, J MED CHEM, 42(13), 1999, pp. 2409-2421
Fibrinogen receptor antagonist-induced thrombocytopenia in chimpanzee and rhesus monkey associated with preexisting drug-dependent antibodies to platelet glycoprotein IIb IIIa
Authors: Bednar, B Cook, JJ Holahan, MA Cunningham, ME Jumes, PA Bednar, RA Hartman, GD Gould, RJ
Citation: B. Bednar et al., Fibrinogen receptor antagonist-induced thrombocytopenia in chimpanzee and rhesus monkey associated with preexisting drug-dependent antibodies to platelet glycoprotein IIb IIIa, BLOOD, 94(2), 1999, pp. 587-599
Risultati: 1-20 |